Epidemiology and Risk Factors of 28-day Mortality of Hospital-acquired Bloodstream Infection in Turkish Intensive Care Units: a Prospective Observational Cohort Study
Overview
Authors
Affiliations
Objectives: To uncover clinical epidemiology, microbiological characteristics and outcome determinants of hospital-acquired bloodstream infections (HA-BSIs) in Turkish ICU patients.
Methods: The EUROBACT II was a prospective observational multicontinental cohort study. We performed a subanalysis of patients from 24 Turkish ICUs included in this study. Risk factors for mortality were identified using multivariable Cox frailty models.
Results: Of 547 patients, 58.7% were male with a median [IQR] age of 68 [55-78]. Most frequent sources of HA-BSIs were intravascular catheter [182, (33.3%)] and lower respiratory tract [175, (32.0%)]. Among isolated pathogens (n = 599), 67.1% were Gram-negative, 21.5% Gram-positive and 11.2% due to fungi. Carbapenem resistance was present in 90.4% of Acinetobacter spp., 53.1% of Klebsiella spp. and 48.8% of Pseudomonas spp. In monobacterial Gram-negative HA-BSIs (n = 329), SOFA score (aHR 1.20, 95% CI 1.14-1.27), carbapenem resistance (aHR 2.46, 95% CI 1.58-3.84), previous myocardial infarction (aHR 1.86, 95% CI 1.12-3.08), COVID-19 admission diagnosis (aHR 2.95, 95% CI 1.25-6.95) and not achieving source control (aHR 2.02, 95% CI 1.15-3.54) were associated with mortality. However, availability of clinical pharmacists (aHR 0.23, 95% CI 0.06-0.90) and source control (aHR 0.46, 95% CI 0.28-0.77) were associated with survival. In monobacterial Gram-positive HA-BSIs (n = 93), SOFA score (aHR 1.29, 95% CI 1.17-1.43) and age (aHR 1.05, 95% CI 1.03-1.08) were associated with mortality, whereas source control (aHR 0.41, 95% CI 0.20-0.87) was associated with survival.
Conclusions: Considering high antimicrobial resistance rate, importance of source control and availability of clinical pharmacists, a multifaceted management programme should be adopted in Turkish ICUs.
Vostal A, Grance M, Powers 3rd J, Kadri S, Warner S, Chukwuma U BMJ Open. 2025; 15(3):e094861.
PMID: 40032367 PMC: 11877242. DOI: 10.1136/bmjopen-2024-094861.
Vostal A, Grance M, Powers J, Powers 3rd J, Kadri S, Warner S medRxiv. 2025; .
PMID: 39802776 PMC: 11722484. DOI: 10.1101/2024.10.02.24314780.
Bacterial co-infection in COVID-19: a call to stay vigilant.
Liu S, Yu C, Tu Q, Zhang Q, Fu Z, Huang Y PeerJ. 2024; 12:e18041.
PMID: 39308818 PMC: 11416760. DOI: 10.7717/peerj.18041.
Ntziora F, Giannitsioti E J Intensive Med. 2024; 4(3):269-280.
PMID: 39035613 PMC: 11258508. DOI: 10.1016/j.jointm.2023.12.004.